Table 1.
Relationship between MMP2 promoter methylation status and clinical patients’ data
| N | Methylated (%) | Unmethylated (%) | p value | ||
|---|---|---|---|---|---|
| Cases | 162 | 107 (66.0) | 55 (34.0) | ||
| Tumor grade | I | 10 | 8 (80.0) | 2 (20.0) | 0.009 |
| II | 45 | 37 (82.2) | 8 (17.8) | ||
| III | 24 | 17 (70.8) | 7 (29.2) | ||
| IV | 83 | 45 (54.2) | 38 (45.8) | ||
| Low grade glioma | 55 | 45 (81.8) | 10 (18.2) | 0.002 | |
| High grade glioma | 107 | 62 (57.9) | 45 (42.1) | ||
| Gender | Male | 73 | 50 (68.5) | 23 (31.5) | 0.552 |
| Female | 89 | 57 (64.0) | 32 (36.0) | ||
| Age, yr | > 60 | 51 | 31 (60.8) | 20 (39.2) | 0.337 |
| ≤ 60 | 111 | 76 (68.5) | 35 (31.5) | ||
| Survival (months) | > 24 | 67 | 53 (79.1) | 14 (20.9) | 0.003 |
| ≤ 24 | 95 | 54 (56.8) | 41 (43.2) |